E Fund Management Co. Ltd. Increases Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

E Fund Management Co. Ltd. boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 37.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,551 shares of the company’s stock after purchasing an additional 4,476 shares during the period. E Fund Management Co. Ltd.’s holdings in Intellia Therapeutics were worth $505,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. ARK Investment Management LLC lifted its position in shares of Intellia Therapeutics by 14.7% during the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock valued at $347,966,000 after buying an additional 1,463,820 shares in the last quarter. Rhenman & Partners Asset Management AB lifted its position in shares of Intellia Therapeutics by 1,600.0% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 850,000 shares of the company’s stock valued at $26,877,000 after buying an additional 800,000 shares in the last quarter. Vestmark Advisory Solutions Inc. purchased a new position in shares of Intellia Therapeutics during the 4th quarter valued at about $8,110,000. Federated Hermes Inc. lifted its position in shares of Intellia Therapeutics by 13.8% during the 4th quarter. Federated Hermes Inc. now owns 2,016,300 shares of the company’s stock valued at $61,477,000 after buying an additional 244,722 shares in the last quarter. Finally, abrdn plc purchased a new position in shares of Intellia Therapeutics during the 4th quarter valued at about $4,704,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group cut Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $136.00 to $32.00 in a research report on Friday, February 23rd. Wolfe Research initiated coverage on Intellia Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating on the stock. Canaccord Genuity Group lifted their target price on Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Finally, Wedbush reissued a “neutral” rating and set a $29.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Intellia Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $67.00.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA traded down $0.88 during trading hours on Wednesday, reaching $23.00. The stock had a trading volume of 1,373,978 shares, compared to its average volume of 1,474,757. Intellia Therapeutics, Inc. has a 52 week low of $19.37 and a 52 week high of $47.48. The company has a 50 day moving average price of $25.64 and a two-hundred day moving average price of $27.22. The stock has a market capitalization of $2.22 billion, a PE ratio of -4.25 and a beta of 1.85.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. The business had revenue of ($1.92) million for the quarter, compared to the consensus estimate of $15.10 million. During the same quarter in the previous year, the company posted ($1.40) EPS. Equities research analysts predict that Intellia Therapeutics, Inc. will post -5.57 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In other news, EVP James Basta sold 2,297 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the transaction, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 3.00% of the company’s stock.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.